Genentech to Present New and Updated Data for Seven Approved and Investigational Medicines Across Multiple Types of Breast Cancer at the 2019 San…

November 18th, 2019 4:44 am

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 18, 2019--

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from a number of studies across its growing breast cancer portfolio will be presented at the San Antonio Breast Cancer Symposium (SABCS) on December 10-14, 2019. These data include new results in HER2-positive breast cancer and studies of new molecules in hormone receptor-positive (HR-positive) breast cancer.

For the past three decades, we have remained dedicated to improving outcomes for people with breast cancer, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. This sustained commitment is exemplified by new data for our approved and investigational medicines across the spectrum of breast cancer being presented at SABCS this year.

Key presentations

New data will be presented from a second interim overall survival (OS) analysis of the Phase III APHINITY trial evaluating Perjeta (pertuzumab) and Herceptin (trastuzumab) plus chemotherapy (the Perjeta-based regimen), compared to Herceptin and chemotherapy, as an adjuvant treatment for HER2-positive early breast cancer (eBC). This latest interim OS analysis also includes updated descriptive invasive disease-free survival and cardiac safety data.

Genentech will also present data from the primary analysis of the Phase III FeDeriCa study which evaluated a new investigational fixed-dose combination (FDC) of Perjeta and Herceptin administered as a single subcutaneous formulation in combination with intravenous chemotherapy. The FDC is administered under the skin in just minutes, significantly reducing the time spent receiving treatment and providing people with HER2-positive breast cancer a potential new treatment option for faster delivery of the Perjeta-based regimen.

Data will also be presented from studies in HR-positive breast cancer, including findings from early studies investigating Genentechs pipeline molecules GDC-9545, a selective estrogen receptor degrader, and GDC-0077, a mutant selective PI3K inhibitor.

Overview of Genentech studies to be presented at SABCS 2019

Medicine(s)

Abstract title

Abstract number

(date, time, location of presentation)

HER2-positive breast cancer

Perjeta and Herceptin

Interim OS analysis of APHINITY (BIG 4-11): a randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive eBC

Abstract GS1-04

(Oral)

Wednesday, December 119:30 9:45 AM CST

Hall 3

Perjeta and Herceptin

Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: final analysis of the Phase IIIb, multicenter, open-label, single-arm MetaPHER study

Abstract P1-18-05

(Poster)